ARWR — Arrowhead Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$83.27
+$0.53 (+0.64%)
Arrowhead Pharmaceuticals Inc (ARWR) is a biotechnology company listed on NASDAQ. It is led by Christopher R. Anzalone Ph.D., based in 177 East Colorado Boulevard, Pasadena, CA, United States, 91105, with about 711 employees. Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Latest reported ARWR revenue for 2025-09-30 was $829.4M. Net income was $30.1M. Revenue was up 2887.2% from 2025-06-30 to 2025-09-30. ARWR currently screens at market cap $10.59B.
Use this ARWR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ARWR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ARWR SEC filings page. Lician reads the product cache first so this HTML stays unique to Arrowhead Pharmaceuticals Inc even when a live quote feed is slow.
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
ARWR Key Statistics
Market Cap
$10.59B
Volume
306,795
Previous Close
$86.73
Day Range
$87.00 – $90.21
EPS
-$0.01
Revenue
$829.45M
Net Income
$30.11M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+23258.2%
Profit Margin
3.6%
Employees
711
ARWR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $829.45M | $3.55M | $240.74M | $243.23M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $30.11M | -$609.69M | -$209.28M | -$176.49M |
| EPS (Diluted) | -$0.01 | -$5.00 | -$1.92 | -$1.67 |
Total Assets
$1.39B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$0.00
Operating Cash Flow
$179.55M
Free Cash Flow
$0.00
Arrowhead Pharmaceuticals Inc Company Information
- Chairman, CEO & President
- Christopher R. Anzalone Ph.D.
- Headquarters
- 177 East Colorado Boulevard, Pasadena, CA, United States, 91105
- Website
- arrowheadpharma.com
- Phone
- 626 304 3400
- IPO / Founded
- 1993-06-16
- Sector
- Healthcare
- Industry
- Biotechnology